Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment

British Journal of Cancer
Koji TakadaMasaichi Ohira

Abstract

Immune responses in a tumour microenvironment can be evaluated by analysing tumour-infiltrating lymphocyte (TIL) density; this has been verified in the clinical setting. Although there are many reports on TIL density in primary tumours, little is known about its density in recurrent tumours. Of 300 patients treated with neoadjuvant chemotherapy during the study period, 29 were considered for evaluation of TIL density in primary and recurrent tumours. We performed a retrospective analysis of the association between TIL density and prognosis. TIL density was significantly lower in recurrent tumours than in primary tumours (P = 0.007). There was no correlation between post-recurrence survival and TIL density in core-needle biopsy specimens obtained from primary tumours (P = 0.837). However, patients with high TIL density in recurrent tumours had significantly better post-recurrence survival than did the corresponding group with low TIL density (P = 0.041). Multivariate analysis revealed that high TIL density contributed significantly towards improving post-recurrence survival in all patients (P = 0.035; hazard ratio, 0.167). In recurrent breast cancer, a decrease in TILs density was observed as compared to the primary tumour, and ...Continue Reading

References

Feb 3, 2005·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa M McShaneUNKNOWN Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics
Apr 20, 2007·The Cochrane Database of Systematic Reviews·J S D MieogC J H van de Velde
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jan 27, 2009·Journal of Surgical Oncology·Frederick L Greene, Leslie H Sobin
Jul 15, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C LiedtkeA M Gonzalez-Angulo
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagen KenneckeKaren Gelmon
Jun 29, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Aug 26, 2011·The Breast : Official Journal of the European Society of Mastology·Seho ParkByeong-Woo Park
Nov 30, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eitan AmirMark Clemons
Sep 25, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciV Guarneri
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvia AdamsSunil S Badve
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Dec 24, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertSibylle Loibl
Oct 27, 2015·BMC Surgery·Shinichiro KashiwagiKosei Hirakawa
Dec 17, 2015·Nature Reviews. Clinical Oncology·Peter SavasSherene Loi

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies

Software Mentioned

JMP

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.